Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer.
Adenocarcinoma of Lung
/ drug therapy
Adult
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Carcinoma, Squamous Cell
/ drug therapy
Diffusion Magnetic Resonance Imaging
/ methods
Female
Follow-Up Studies
Humans
Immune Checkpoint Inhibitors
/ therapeutic use
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Movement
Prognosis
Prospective Studies
Survival Rate
Anti-PD-1 therapy
Anti-programmed death-1 therapy
Atypical radiologic response
IVIM-MRI
Immune therapy
Pseudoprogression
Journal
Lung cancer (Amsterdam, Netherlands)
ISSN: 1872-8332
Titre abrégé: Lung Cancer
Pays: Ireland
ID NLM: 8800805
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
19
11
2019
revised:
26
02
2020
accepted:
13
03
2020
pubmed:
24
3
2020
medline:
13
4
2021
entrez:
24
3
2020
Statut:
ppublish
Résumé
Conventional evaluation of anti-tumor activity on the basis of tumor size is inadequate for immune checkpoint inhibitors (ICIs). We therefore aimed to assess the usefulness of intravoxel incoherent motion magnetic resonance imaging (IVIM-MRI) for evaluation of the therapeutic efficacy of ICIs. A chest IVIM-MRI was performed before and 2, 4, and 8 weeks after administration of ICIs in patients with advanced non-small-cell lung cancer. Apparent diffusion coefficient (ADC), skewness of ADC (ADC Twenty patients were enrolled in this study. An increased ADC 8 weeks and decreased ADC Changes in histograms of ADC may be useful for predicting long-term efficacy and distinguishing between pseudoprogression and actual PD after ICIs.
Identifiants
pubmed: 32203770
pii: S0169-5002(20)30343-3
doi: 10.1016/j.lungcan.2020.03.013
pii:
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
47-54Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.